Abstract |
One hundred and sixty black South African gold miners with acute pneumococcal pneumonia were enrolled in a prospective randomized double-blind trial comparing roxithromycin (150 mg 2 X day) with cephradine (1.0 g 2 X day). Ninety patients with pneumonia caused by Streptococcus pneumoniae were treated for 5-10 days. Forty-three of 46 (93.4%) of the roxithromycin and all 44 (100%) of the cephradine treated groups had satisfactory clinical responses. In eight of the 46 (17%) roxithromycin treated patients and 10 of the 44 (23%) cephradine treated patients, Streptococcus pneumoniae was not eradicated from sputum cultures by the tenth day. Side effects in 18 patients (20%) were mild and were usually manifested by elevation of the transaminases; these were more common in the cephradine group (12) than in the roxithromycin group (5). Roxithromycin appears to be a safe and effective oral antibiotic for treatment of patients with mild to moderate pneumococcal pneumonia.
|
Authors | B J Zeluff, P Lowe, H J Koornhof, L O Gentry |
Journal | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
(Eur J Clin Microbiol Infect Dis)
Vol. 7
Issue 1
Pg. 69-71
(Feb 1988)
ISSN: 0934-9723 [Print] Germany |
PMID | 3132383
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Bacterial Agents
- Cephalosporins
- Leucomycins
- Cephradine
|
Topics |
- Adult
- Anti-Bacterial Agents
(therapeutic use)
- Black People
- Cephalosporins
(therapeutic use)
- Cephradine
(therapeutic use)
- Clinical Trials as Topic
- Double-Blind Method
- Humans
- Leucomycins
(therapeutic use)
- Male
- Middle Aged
- Occupational Diseases
(drug therapy)
- Pneumonia, Pneumococcal
(drug therapy)
- Prospective Studies
- Random Allocation
- South Africa
- Sputum
(microbiology)
|